The Effect of Brachial Plexus Nerve Block on Distal Peripheral Nerve Conduction
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Contacts and Locations
Study Locations
-
-
Maryland
-
Fort Meade, Maryland, United States, 20755
- Fort Meade
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male and female military health care beneficiaries 18 years and older, capable of providing informed consent indicating awareness of the investigational nature of the study, in keeping with institutional policy
- Written informed consent must be obtained from each patient prior to entering the study
- Patients must be willing to have a regional anesthetic nerve block placed prior to their scheduled procedure
- Patients must be willing to have neurodiagnostic tests performed prior to placement and after placement of the regional anesthesia nerve block
Exclusion Criteria:
- Refusal to have a brachial plexus nerve block placed
- Refusal to have serial nerve conduction studies performed
- Contraindication for a regional anesthesia nerve block (allergy to local anesthetic, infection at site of injection, elevated coagulation time)
- Presence of conditions affecting the hand or arm (e.g., injury, infection) that might preclude the performance of nerve conduction studies
- Presence of known major abnormalities of nerve conduction, e.g., absent median sensory potential in a patient scheduled for carpal tunnel release
- Presence of conditions affecting the contralateral hand or arm (e.g., injury, infection) that might preclude the performance of sensory and motor studies to test block or absence of a contralateral upper extremity
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Compund Muscle Action Potential (CMAP) amplitude
Time Frame: 1 day
|
measured for motor studies from baseline to peak in mV
|
1 day
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Distal Latency
Time Frame: 1 day
|
the interval between the stimulation of a compound muscle and the observed response.
Normal nerve conduction velocity is above 40 m/sec in the lower extremities and above 50 m/sec in the upper extremities, but age, muscle disease, temperature, and other factors can influence the velocity.
|
1 day
|
|
Peak Latency
Time Frame: 1 day
|
|
1 day
|
|
Onset Latency
Time Frame: 1 day
|
|
1 day
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- 365681-8
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.